Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and A(B)VD in Front-line High Risk Hodgkin Lymphoma
NCT03033914Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2017
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nivolumab in Hodgkin lymphoma (HL), sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2017; status: active, not recruiting.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03033914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03033914.